Edison Investment - NovaBay Pharmaceuticals - Q113 sets the scene - Tuning in for a crescendo of data

07:08 EDT 13 May 2013 | BioPortfolio

NovaBay’s Q113 results set the scene for a potentially transformational second half of 2013, with results expected from three Phase II studies of its topical anti-infective, auriclosene (NVC-422). We currently value the company at $71m, or $1.90 per share, but successful outcomes in all three trials (urinary catheter irrigation, impetigo and viral conjunctivitis, in order of increasing value) could boost our indicative value to approximately $130m, or $3.50 per share (assuming no significant dilution). Positive data would also provide further financing and partnership opportunities.

Source: Edison Investments -


More From BioPortfolio on "Edison Investment - NovaBay Pharmaceuticals - Q113 sets the scene - Tuning in for a crescendo of data"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...